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Abstract
Background Since the introduction of the five-level ver-
sion of the EQ-5D (5L), many studies have comparatively
investigated the measurement properties of the original
three-level version (3L) with the 5L version.
Objective The aim of this study was to consolidate the
available evidence on the performance of both instruments.
Methods A systematic literature search of studies in the
English and German languages was conducted (2007–
January 2018) using the PubMed, EMBASE, and Psy-
cINFO (EBSCO) databases, as well as the EuroQol
Research Foundation website. Data were extracted and
assessed on missing values, distributional properties,
informativity indices (Shannon’s H0 and J0), inconsisten-
cies, responsiveness, and test–retest reliability.
Results Twenty-four studies were included in the review.
Missing values and floor effects (percentage reporting the
worst health state) were found to be negligible for both 3L
and 5L (\5%). From 18 studies, inconsistencies ranged
from 0 to 10.6%, although they were generally well below
5%, with 9 studies reporting the most inconsistencies for
Usual Activities (mean percentage 4.1%). Shannon’s
indices were always higher for 5L than for 3L, and all but
three studies reported lower ceiling effects (‘11111’) for 5L
than for 3L. There is mixed and insufficient evidence on
responsiveness and test–retest reliability, although results
on index values showed better performance for 5L on test–
retest reliability.
Conclusion Overall, studies showed similar or better
measurement properties of the 5L compared with the 3L,
and evidence indicated moderately better distributional
parameters and substantial improvement in informativity
for the 5L compared with the 3L. Insufficient evidence on
responsiveness and test–retest reliability implies further
research is needed.
Key Points for Decision Makers
This review supports the use of both the 3L and the
5L in a broad range of patients, populations and
countries.
The 5L showed better or at least similar
measurement properties when compared to the 3L.
Evidence on responsiveness is inconclusive and
requires further research.
1 Introduction
The EQ-5D is one of the most widely used instruments to
describe and value health [1, 2]. It is a generic, self-com-
pletion questionnaire consisting of two parts: a 5-item
descriptive system and a thermometer-like visual analogue
scale ranging from 0 to 100 (the EQ-VAS). It comprises five
items, each describing one dimension [Mobility (MO), Self-
Care (SC), Usual Activities (UA), Pain/Discomfort (PD),
and Anxiety/Depression (AD)]. The original questionnaire,
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introduced in 1990 [3], allows respondents to choose
between three options; level 1, representing no problems;
level 2, reflecting small or moderate problems; and level 3,
indicating extreme problems (or ‘unable to’). Self-ratings on
the three levels in the five dimensions (items) can be sum-
marized to produce 243 health states, also known as a health
profile. Health profiles can be assigned index values derived
from econometric techniques to elicit societal preference
weights. These index values can then be used in economic
evaluation of health programs [1, 4].
The EQ-5D was conceptualized to capture deviations
from ‘normal’ health, thereby focusing on self-reported
health and health-related quality-of-life problems while not
attempting to capture aspects beyond health. Internation-
ally, it is currently one of the most widely used preference-
based quality-of-life questionnaires. A large body of liter-
ature demonstrates that the instrument is valid and reliable
[5–7]. However, although the EQ-5D was developed to
supplement other instruments, this simple and short mea-
sure has been increasingly used as a ‘stand-alone tool’
[8, 9]. The increase in use of the EQ-5D in the field of
health technology assessment raises concerns about
methodological measurement issues [10]. The first is the
EQ-5D’s ceiling effect, or a high proportion of participants
reporting ‘no problems’ on one or all dimensions [11–13].
Second, some studies found the EQ-5D to be less respon-
sive to changes in health compared with other preference-
based measures [e.g. Health Utility Index (HUI), Short-
Form 6-Dimension (SF-6D), Quality of Well-Being Scale–
Self Administered (QWB-SA)] [14–21]. To address these
concerns, paired with the inherent aspiration of the ever-
expanding research community to continually improve the
instrument, a new version of the EQ-5D was developed by
the EuroQol group [22–24]. The new version expanded the
response choices from three to five levels and changed the
wording of some of the response categories (Table 1). The
new version is called the EQ-5D-5L [25], and can describe
3125 (= 55) health conditions.
Since introducing the EQ-5D-5L in 2011, many studies
have comparatively investigated the measurement proper-
ties of the original EQ-5D (now interchangeably referred to
as EQ-5D-3L or 3L) and the newer EQ-5D-5L (now inter-
changeably referred to as EQ-5D-5L or 5L). In this review
we summarize the consolidated findings from these studies.
2 Methods
2.1 Data Sources, Search Strategy, Study Selection,
and Inclusion and Exclusion Criteria
We conducted a systematic literature search to identify all
studies in the English and German languages comparing
the 3L and the 5L published between January 2007 and
May 2016 using the following keywords: ‘EQ-5D-5L’,
‘EQ-5D 5L’, ‘EuroQol AND 5L’, ‘EuroQoL AND 5 level’.
Electronic searches were performed in the PubMed,
EMBASE, and PsycINFO (EBSCO) databases, in addition
to the EuroQol Research Foundation website, for relevant
publications. The inclusion criteria were primary study or
conference paper comparing the final versions of the 3L
and the 5L(studies using experimental versions were
excluded). Articles were further excluded if they did not
assess the EQ-5D, were of another publication type, it was
not an empirical study in adults, were not in English or
German, or were not available in full text. The review was
updated during the process of manuscript revision using the
same search algorithms, and inclusion and exclusion/eli-
gibility criteria as detailed above. The search was con-
ducted in articles published between May 2016 and
January 2018. The process of study selection is shown in
Fig. 1.
2.2 Screening and Data Extraction
Two researchers independently reviewed the title and
abstract of all identified studies, while a third reviewer (TK
or MFJ) was consulted in case of variance. After removing
duplicates, full-text articles were reviewed by one reviewer
(IB) and doubled-checked by the second reviewer (YSF)
for missing extractions. For cases of papers that used the
same data, those with more information on the indicators of
interest were always included. When publications addres-
sed different information based on the same data, both
papers were included. For each article, the following
information was extracted: authors, title and year of pub-
lication, sample characteristics (e.g. sample size, percent-
age of females, mean age), country, outcome measures
used, aims of the study, study design, and parameters
describing relevant measure properties. The measurement
properties were distributional properties, informativity,
inconsistencies, responsiveness and test–retest reliability.
All of these properties were assessed in terms of results
related to the descriptive systems of the 3L and 5L. For
responsiveness and test–retest reliability, results on index
values were also included.
2.3 Quality Assessment of Studies
The quality of the full-text articles included for review was
assessed using a 9-item critical appraisal tool (see the
electronic supplementary material [ESM]). The items were
defined based on the ‘Quality Assessment Tool for
Observational Cohort and Cross-Sectional Studies’ from
the National Heart, Lung, and Blood Institute (NHLBI)
[26], and contained (1) objective/research questions; (2)
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study population; (3) groups recruited/eligibility criteria;
(4) study design; (5) sample size; (6) response rate; (7) data
collection; (8) outcome parameter; and (9) statistical
tests/analysis. Study quality was assessed as excellent,
good, fair or poor, with the corresponding number of cri-
teria fulfilled being 8–9, 5–7, 3–4 or 0–2.
2.4 Distributional Properties
We compared the 3L and 5L on their classical distribution
characteristics, such as the number and proportion of
missing values, the number and percentage reporting the
best (ceiling; ‘no problems’) and worst (floor) level of
health state in each dimension and across all dimensions
(e.g. ‘11111’ and ‘33333’ for the 3L or ‘55555’ for the 5L,
respectively). The results are presented as ranges of per-
centages or numbers of studies in which the 5L performed
equal to, worse than, or better than the 3L (e.g. How often
did more than 15% [as suggested by Terwee et al. [27]] of
the study sample report ‘no problems’ when using the 5L
compared with the 3L?) We used random effects logit
transformation to calculate pooled proportions from single
proportions using R’s ‘meta’ package specifically for pro-
portion reporting ‘no problems’ across all dimensions
(‘11111’). Pooled proportions give an idea of the overall
ceiling effect when taking into account the sample sizes
across included studies.
2.5 Informativity
Shannon’s index is based on information theory and allows
an assessment on the informational and discriminatory
power of each descriptive system.
According to Shannon’s indices, an item is most effi-
ciently used when all responses are evenly distributed
across all response options [28], with a higher index indi-
cating more information captured by the instrument. While
H0 represents the extent to which the information is evenly
distributed across all categories, Shannon’s J0 additionally
takes into account the number of response options or
descriptive categories of the measurement system. J0 can
take values between 0 and 1, with a J0 of 0 representing that
all responses are concentrated in one response level (most
uneven distribution; worst discriminatory power) and 1
representing that all response levels are evenly distributed
(even distribution; best discriminatory power). There is no
straightforward interpretation for H0. Since H0max depends
on the number of levels, within our context H0 can take
values between 0 (no informational richness/discriminatory
power) and 1.58 (log2L, with the number of levels L = 3)
Table 1 Response levels of the
EQ-5D-3L and EQ-5D-5L
3L 5L
Level 1 No problems Level 1 No problems
Level 2 Slight problems
Level 2 Some/moderate problems Level 3 Moderate problems
Level 4 Severe problems
Level 3 Extreme problems/unable to Level 5 Extreme problems/unable to
When expanding from the 3L to the 5L, some of the wording of response categories was changed. The most
significant was that level 3 mobility of the 3L was changed from ‘confined to bed’ to ‘unable to walk about’
for level 5 of the 5L [24]
Fig. 1 Literature search and
selection process
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for the 3L and 2.32 (log2L, with L = 5) for the 5L (which
corresponds to the highest informational richness/discrim-
inatory power).
Within this review, H0 and J0 were extracted from the
studies or calculated using these formulas, where pi is the
proportion of responses in the ith response option:
H0 ¼ 
XL
i¼1
pi log2 pið Þ
J0 ¼ H
0
H0max
Both indices are reported for each EQ-5D dimension.
We aggregated the mean information gain by the 5L, which
was calculated through dividing Shannon’s H0 of the 5L by
Shannon’s H0 of the 3L (H05L/H03L) and Shannon’s J0 for
the 5L by Shannon’s J0 for the 3L (J05L/J03L), respectively,
with H0/J0C1 showing the 5L descriptive classification
system to be more informative than the 3L.
2.6 Inconsistencies
Due to the two additional response levels, we expect a
redistribution that can be quantified with the help of the
parameters already described (i.e. classical distribution
properties on the one hand and Shannon’s indices on the
other). In order to assess whether this redistribution of
responses is conclusive in terms of content, we also con-
sidered inconsistent responses, as defined by Janssen et al.
[8], as a qualitative distribution parameter, or if, and to
what degree, 3L and 5L response pairs differ from each
other. Operationally, we (1) transformed the 3L response
levels 1, 2 and 3 to 5L response levels 1, 3 and 5 to cal-
culate (2) the size of difference of corresponding responses.
Paired responses differing more than one level were
defined as ‘inconsistent’, with a size of inconsistency
ranging from 1 to 3. All studies included in the review used
the methods of Janssen et al. [8] to calculate
inconsistencies.
We report and compare the percentage of inconsisten-
cies by dimension, the range of percentage of inconsis-
tencies by dimension, and the total number and average of
inconsistencies. Notwithstanding the fact that the mere
presence of inconsistent responses does not provide any
information about the underlying causes, their considera-
tion is of particular interest when they occur systemati-
cally, e.g. only in certain patient groups, which could affect
validity, responsiveness and reliability.
2.7 Responsiveness
To evaluate how the instruments capture changes in health
over time, we collected all reported distribution-based
effect sizes (ESs), such as the standardized ES and the
standardized response mean (SRM), and non-parametric
test statistics, such as the Wilcoxon signed-rank order test
or the probability of superiority (PS) as defined by Grissom
and Kim [29]. The ES is the mean change divided by the
standard deviation of the baseline measurement. It disre-
gards the variation in change which is considered by the
SRM (the ratio of the mean change to the standard devia-
tion of the change). The Wilcoxon test is the non-para-
metric equivalent of the t-test for dependent samples and is
applied when the prerequisites for a parametric procedure
are not met.
2.8 Test–Retest Reliability
Several methods can determine whether a measurement
tool consistently produces the same results if the attribute
of interest remains stable [30, 31]. We extracted and
summarized any reported information regarding the mag-
nitude of agreement of data collected at two points in time:
intraclass correlation coefficients (ICCs), Cohen’s Kappa
(j), weighted Kappa (wj), and percentage of agreement
(POA).
An ICC quantifies the dependency of interval-scaled
data pairs if the order of measurement is negligible. Values
range from -1 to 1 with values less than 0 indicating a
reliability of 0 and values higher or equal to 0.70 indicating
good reliability [32].
j is the most widely used measure to assess the agree-
ment for categorical data [33]; it measures the random
corrected degree of agreement between two ratings. In
contrast to the simple percentage of agreement of two
ratings, it considers that ratings will sometimes agree or
disagree by chance. When additionally taking into account
the size of the deviation (one vs. several categories) within
ordinal-scaled data (such as the EQ-5D responses), calcu-
lating wj is indicated [34]. Kappa is 1 if two ratings per-
fectly match, and 0 when agreement equals chance. Kappa
is negative if the match is poorer than chance [35]. Note
that a wj using quadratic weights is one type of ICC. Based
on the Guidelines for Reporting Reliability and Agreement
Studies (GRRAS), a j[ 0.40 and ICCs[0.6 were con-
sidered acceptable [30].
3 Results
Of the 497 studies identified from the search, 215 were
selected for full-text review based on title and abstract
screening. Of those, 190 did not meet the inclusion criteria
and were excluded. The remaining 20 articles that com-
pared methodical properties of the official versions of the
3L and 5L were included in the review (Fig. 1 [36–59]).
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An update carried out in the course of the manuscript
revision resulted in a further four hits, therefore the final
review is based on a total of 24 articles. All papers were of
good to excellent quality (see the ESM).
The sample size of the included articles ranged from 50
to 7294 for the 3L, and 50 to 6800 for the 5L (Table 2).
Data were collected in 18 different countries in the fol-
lowing settings: general population (8 studies) and patient
populations (16 studies). All but two studies directly
compared the 3L and the 5L (head-to-head, i.e. the same
respondents completed both the 3L and 5L questionnaires).
In head-to-head comparison studies, the 5L was adminis-
tered before the 3L (Table 3). Two of the crossover studies
(i.e. studies that randomized the administration order of the
3L and 5L) reported that order of administration had no
influence on response trends [37, 43].
3.1 Missing Values and Distributional Properties
Fifteen studies reported missing values below 5% for both
3L (range for the dimensions: 0–1.9%; range for the pro-
file: 0–6.6%) and 5L (range for the dimensions: 0–1.6%;
range of the profile: 0–4.0%). One study found 8.5% left
the 5L blank and 0.8% left the 3L blank entirely, which is
probably due to the methodology of how the 3L is first
presented in this study [52]. Floor effects by dimension
were reported in 19 studies and were almost always below
5% (3L: 0–26.1%; 5L: 0–6.5%) [Table 4]. Mean absolute
reduction in floor effects ranged from 0.16 percentage
points (Usual Activities) to 4.18 percentage points (Pain/
Discomfort). For the profile, floor effects ranged from 0 to
2.7% for the 3L and 0 to 1.8% for the 5L (five studies).
All studies reported information on the number or pro-
portion reporting ‘no problems’ in any dimension or for the
profile (‘11111’) [Table 4]. The percentage reporting ‘no
problems’ ranged from 2.3 to 99.5% for the 3L and from
0.6 to 99.5% for the 5L. Using the 5L could reduce ceiling
effects up to 16.9 percentage points (Mobility) to 30.0
percentage points (Self-Care). The highest absolute
reduction of ceiling effects was found for Self-Care (-1.3
to 30.0 percentage points), followed by Pain/Discomfort
(1.5 to 20.0 percentage points), and Anxiety/Depression (-
3.4 to 19.7 percentage points). Regarding the profile, full
health state profiles were reported for 0.6 to 68.0% of the
samples studied with the 3L, compared with 0 to 55.0% of
the samples studied with the 5L (Fig. 2).
Figure 3 presents the pooled ceiling effects (proportion
reporting ‘11111’) for studies using patient (16 studies) and
population (8 studies) samples. The pooled proportion of
ceiling in the patient population was 0.23 [confidence
interval (CI) 0.170–0.296] for 3L and 0.18 (CI
0.131–0.238) for 5L. Furthermore, the pooled proportion of
ceiling in population-based studies was 0.53 (CI
0.474–0.593) for 3L, compared with 0.43 (CI 0.369–0.492)
for 5L. The pooled proportions did not change substantially
when excluding the two studies that did not use direct
head-to-head comparisons (3L = 0.55, CI 0.472–0.623;
5L = 0.44, CI 0.367–0.517).
3.2 Informativity
Fourteen studies provided information on Shannon’s H0
and Shannon’s J0. In general, Shannon’s H0 was always
higher in the 5L than in the 3L, and Shannon’s J0 was
higher for the 5L than the 3L, in all but five studies. Across
all studies and dimensions, mean Shannon’s H0 ranged
from 0.72 to 1.43 for the 5L and from 0.47 to 0.98 for the
3L (Fig. 4). Mean information gain for Shannon’s H0 (H05L/
H03L) ranged from 1.44 for Anxiety/Depression to 1.65 for
Mobility. Shannon’s J0 differences between the 3L and the
5L were marginal (Fig. 4), with a mean information gain
(J05L/J03L) ranging from 1.02 for Self-Care to 1.16 for
Mobility.
3.3 Inconsistencies
Eighteen studies provided information on inconsistencies.
The total number and proportion of inconsistencies were,
with four exceptions, well below 5%, ranging from 0 to
10.6% across 18 studies (Fig. 5). The most inconsistencies
were reported for Usual Activities (mean percentage
4.1%), whereas the lowest number of inconsistencies was
found for Mobility (2.5%). The total proportion of incon-
sistencies was lowest (range 0–5.4%) in healthy and
chronic populations and highest (range 6–10.6%) in
orthopedic settings (Fig. 5).
3.4 Responsiveness
Of the three studies analyzing responsiveness, two studies
examined the index-level utility scores (using preference-
based weights) [42, 45], whereas one study assessed
responsiveness on the dimensional-level using percentage
of improved, stable and deteriorated patients, and PS, a
measure defined by Grissom and Kim [29, 37]. Distribu-
tion-based ES measures were only included in one of these
studies [42]. In this longitudinal cohort, stroke patients
were classified into three groups of improved, stable and
deteriorated patients based on two external criteria: the
Barthel Index and the modified Rankin Scale. Although
both the 3L and the 5L were responsive, showing moderate
ES and SRM, the 5L appeared to be (slightly) less
responsive than the 3L but more responsive than the EQ-
VAS. The other two studies overall found better respon-
siveness for the 5L compared with the 3L when using non-
parametric test statistics in populations of liver disease
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Table 2 Characteristics of the studies included in this systematic review
Reference,
year
Country Sample size [n]
(response rate)
Setting Patient population Percentage
of women
Mean age ± SD
(range) in years
Agborsangaya
et al. 2014
[36]
Canada n3L = 4946
(98.7%)
n5L = 4752
(98.9%)
General
population
Respondents of two consecutive survey
cycles of the Health Quality Council
of Alberta Patient Experience and
Satisfaction Survey for 2010 and
2012
3L: 52.3
5L: 55.7
3L: 46.6 ± 16.5
5L: 47.7 ± 17.1
Buchholz et al.
2015 [37]
Germany nt1 = 230,
nt2 = 224,
nt3 = 154
(NA)
Inpatient
rehabilitation
n = 114 orthopedic, n = 54
psychosomatic, n = 62
rheumatologic inpatient rehabilitation
patients
69.6 57 ± 12 (26–86)
Conner-Spady
et al. 2015
[38]
Canada 176 (58%) Orthopedic Patients with osteoarthritis who were
referred to an orthopedic surgeon for
total joint replacement
60 65 ± 11 (25–88)
Craig et al.
2014 [39]
US 2614 (91%) General
population
Patients with chronic conditions
(national representative adult
population sample)
49 NR
Feng et al.
2015 [40]
England 3L: 7294 (64%)
5L: 996 (50%)
General
population
3L: participants were included in the
2012 Health Survey for England, and
patients were included in the EQ-5D-
5L valuation study, selected at
random from residential post codes
3L: 55.6
5L: 59.3
NR
Ferreira et al.
2016 [56]
Portugal 624 (NR) Young general
population
(Under-) graduate students from two
Portuguese universities aged
B30 years
60.4 21.7 ± 3.2
Golicki et al.
2015a [41]
Poland 408 (NR) Patients during
index
hospitalization
(stroke)
Acute stroke patients (types:
subarachnoid hemorrhage, n = 8;
intracerebral hemorrhage, n = 39;
cerebral infarction, n = 353; stroke,
not specified, n = 4)
48.5 69.0 ± 12.9
(23–98)
Golicki et al.
2015b [42]
Poland 114 (NR) Hospitalized
patients at
1 week and
4 months
poststroke
Patients with primary or recurrent
stroke: 93% ischemic stroke, many
comorbidities (72% hypertension,
25% diabetes, 31% coronary artery
disease)
51.8 70.6 ± 11.0
(39–88)
Greene et al.
2014 [43]
US nt1 = 50 (79%)
nt2 = 77 (80%)
Orthopedic Patients with hip pain and never had a
hip arthroplasty undergoing their first
total hip replacement
NR t1: 63 ± 13 (NR)
t2: 66 ± 10 (NR)
Janssen et al.
2013 [44]
DK, UK,
NL, PL,
I, SCO
3919 (NA) Mixed COPD/asthma (n = 342), depression
(n = 250), diabetes (n = 284), liver
disease (n = 645), personality
disorders (n = 384), rheumatoid
arthritis/arthritis (n = 372), stroke
(n = 614), students (n = 443)
52 51.9 ± 20 (18–NR)
Jia et al. 2014
[45]
China nt1 = 369
outpatients
(34.7%) and
276 inpatients
(62.0%)
nt2 = 183
inpatients
(66.3%)
Clinical (hospital
for infectious
diseases)
Patients with liver diseases 25.0 43.9 ± NR (NR)
Khan et al.
2016 [46]
UK nt1 = 97 (99%)
nt2 = 78 (79%)
nt3 = 41 (55%)
Clinical Single cohort, prospective (non-
interventional) follow-up study in
non-small cell lung cancer patients
44 NR (39–86)
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patients and inpatient rehabilitation patients (Table 5)
[37, 45]. Importantly, the two studies [42, 45] that analyzed
the EQ-5D-5L on the index-level estimated index values
using the crosswalk method, which maps 3L preference
weights onto the 5L responses, which should be considered
when interpreting these results.
3.5 Test–Retest Reliability
Six articles studied the reproducibility of the EQ-5D
measure, with all but one specifying two or more measures
of agreement. ICC was used in all six studies—wj and
POA in three studies, and Kappa in two studies. The time
Table 2 continued
Reference,
year
Country Sample size [n]
(response rate)
Setting Patient population Percentage
of women
Mean age ± SD
(range) in years
Kim et al.
2013 [47]
South
Korea
nt1 = 600
nt2 = 100
General
population
Nationally representative general
population
t1: 50.5
t2: 49.0
t1: 44.9 ± 15.3
(19–88)
t2: 45.3 ± 15.8
(19–88)
Kim et al.
2012 [48]
South
Korea
nt1 = 893
(38.5%)
nt2 = 78 (31.2)
Ambulatory
cancer centre
Patients receiving chemotherapy over a
1-month period
t1: 56.8
t2: 56.4
t1: 53.0 ± 11.2
t2: 53.9 ± 10.9
Pan et al. 2015
[49]
China 289 (96.3%) Hospitalized
outpatients
Diabetes mellitus type II patients with
and without clinical conditions (47%
retinopathy, 37.7% neuropathy,
31.8% arthritis, 24.6% dermopathy,
19.7% heart disease)
69.5 64.9 ± 9.1 (NR)
Pattanaphesaj
et al. 2015
[50]
Thailand 117 (NR) Clinical Diabetes mellitus patients treated with
insulin (54.7% type 2, 45.3% type 1)
62.4 45 ± NR
(aged C12 years)
Poo´r et al.
2017 [57]
Hungary 238 (NA) Clinical;
academic
dermatology
clinic
Inpatient and outpatient (88.7%)
psoriatic patients; 73.1% diagnosed
with a moderate-to-severe psoriasis;
mean disease duration: 18.1 years
(3 months to 52 years)
37.4 47.4 ± 15.2 (NR)
Scalone et al.
2011 [51]
Italy 426 (NA) Clinical Chronic hepatitis C (25.4%), chronic
hepatitis B (22.5%), cirrhosis
(20.9%), liver transplantation
(19.0%), and other chronic hepatic
diseases
31 NR (19–84)
Scalone et al.
2013 [52]
Italy 1088 (NA) Clinical Liver diseases 38 59 ± (18–89)
Scalone et al.
2015 [53]
Italy 6800 (NA) General
population
Representative sample 52.0 51.9 ± 17.6
(18–101)
Shiroiwa et al.
2015 [54]
Japan 1143 (NA) General
population
The study oversampled younger people
due to sampling design
51.2 NR
Wang et al.
2016 [55]
Singapore 121 (NA) Diabetes clinic
of a tertiary
hospital
Outpatients with type 2 diabetes
mellitus
43 55.5 ± 12.7
Yfantopoulos
et al. 2017a
[58]
Greece 2279 (22.5) General
population
Middle-aged and elderly general
population
52.1 57.3 ± 12.4
Yfantopoulos
et al. 2017b
[59]
Greece 396 (NR) Clinical; 16
private
practicing
centers
Psoriatic patients who were to initiate
treatment with calcipotriol plus
betamethasone dipropionate in a fixed
gel combination under routine clinical
practice; 34.6% mild psoriasis, 52.8%
moderate psoriasis
39.9 52.0 ± 16.5
NR not reported, NA not applicable, SD standard deviation, n sample size, n3L sample size reported for the 3L, n5L sample size reported for the
5L, nt1 sample size reported for baseline, nt2 sample size reported for the first follow-up, nt3 sample size reported for the second follow-up, t1
baseline, t2 first follow-up, COPD chronic obstructive pulmonary disease, DK Denmark, UK United Kingdom, NL The Netherlands, PL Poland,
I Italy, SCO Scotland, US United States
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Table 3 Study design and type of questionnaire administration of the studies included in this systematic review
Reference,
year
Study design Mode of questionnaire administration Order of administration Type of
comparison
Agborsangaya
et al. 2014
[36]
Cross-sectional Telephone-based questionnaire
administered by random-digit
dialing
NA Indirect
Buchholz et al.
2015 [37]
Longitudinal multicenter
study
Self-complete version on paper Crossover Head-to-
head
Conner-Spady
et al. 2015
[38]
Longitudinal multicenter Self-complete version on paper 5L first Head-to-
head
Craig et al.
2014 [39]
Cross-sectional Web survey/online data collection Random Head-to-
head
Feng et al.
2015 [40]
Value set study for England;
Health Survey for England
Face-to-face, computer-assisted
interviews
NA Indirect
Ferreira et al.
2016 [56]
Convenience sample Self-complete version on paper 5L first Head-to-
head
Golicki et al.
2015a [41]
Cross-sectional Self-complete version on papera NR Head-to-
head
Golicki et al.
2015b [42]
Single-center, observational,
longitudinal cohort study
Self-complete version on paper NR Head-to-
head
Greene et al.
2014 [43]
Prospective First survey: paper-based; second
survey: online or on paper
Crossover Head-to-
head
Janssen et al.
2013 [44]
Multicountry study Paper and pencil in all countries
except England (online)
5L first Head-to-
head
Jia et al. 2014
[45]
Cross-sectional Self-complete version on paper 5L first Head-to-
head
Khan et al.
2016 [46]
Single cohort, prospective,
non-interventional follow-
up study
NR 3L and 5L were assessed at least
1 week apart to avoid potential for
‘carry over’
Head-to-
head
Kim et al.
2013 [47]
Cross-sectional In-person interviews 5L first Head-to-
head
Kim et al.
2012 [48]
Consecutive sample of
patients
Self-complete version on paper 5L first Head-to-
head
Pan et al. 2015
[49]
Consecutive sample of
patients
Self-complete version on paper 5L first Head-to-
head
Pattanaphesaj
et al. 2015
[50]
Convenience sample of
patients
Self-complete version on paper 3L (right column) and 5L (left) on the
same page
Head-to-
head
Poo´r et al.
2017 [57]
Cross-sectional Self-complete version on paper 5L first Head-to-
head
Scalone et al.
2011 [51]
Naturalistic multicenter cost-
of-illness study
Self-complete version on paper 5L first Head-to-
head
Scalone et al.
2013 [52]
Naturalistic multicenter cost-
of-illness study
Self-complete version on paper 5L first Head-to-
head
Scalone et al.
2015 [53]
Large-scale telephone survey Telephone interview Crossover Head-to-
head
Shiroiwa et al.
2015 [54]
Register study Door-to-door survey (mode of
administration: self-complete
version on paper)
5L first Head-to-
head
Wang et al.
2016 [55]
Consecutive sample of
patients
Self-complete version on paper 5L first Head-to-
head
Yfantopoulos
et al. 2017a
[58]
Observational survey Self-complete version on paper Random Head-to-
head
I. Buchholz et al.
interval between repeated measurements varied from 1 to
3 weeks (Table 6). When using ICC, the studies reported
moderate to excellent reproducibility for both 3L and 5L
index scores, with ICC ranging from 0.52 to 0.83 for the 3L
and from 0.69 to 0.93 for the 5L. When using unweighted
Kappa, studies reported good to very good agreement
(j3L = 0.39–0.93, j5L = 0.36–0.98, mean j3L = 0.692,
mean j5L = 0.678), while studies using wj statistics found
mostly fair to moderate agreement (wj3L = 0.31–0.70,
wj5L = 0.33–0.69, mean wj3L = 0.527, mean
wj5L = 0.541). There is no clear pattern of better
reliability for either the 3L or the 5L. POA was always the
same or higher for the 3L when compared with the 5L
(POA3L = 0.78–0.97, POA5L = 0.64–0.97, mean
POA3L = 0.877, mean POA5L = 0.773).
4 Discussion
The EQ-5D-5L was developed to improve the discrimina-
tive and evaluative properties of the EQ-5D-3L. Since
publication of the 5L, a body of evidence has emerged that
Table 3 continued
Reference,
year
Study design Mode of questionnaire administration Order of administration Type of
comparison
Yfantopoulos
et al. 2017b
[59]
Multicenter, prospective
study
Self-complete version on paper Random Head-to-
head
NA not applicable NR not reported, crossover half of the sample started with the 3L/5L
aIn case of aphasia or dementia, the survey was completed by a family member (as a proxy respondent)
Table 4 Results of the floor and ceiling effects
MO SC UA PD AD ‘33333’/
‘55555’
Floor
Range of floor effects for the 3L (%) 0–3.8 0–4.9 0–10.9 0–26.1 0–7.3 0–2.7
Range of floor effects for the 5L (%) 0–3.0 0–3.7 0–6.5 0–5.7 0–2.5 0–1.8
Range of absolute reduction in floor effects (percentage points) -0.9 to 1.7 -0.3 to 1.2 -1.7 to 6.3 0–20.4 0–4.8 0–0.9
Mean absolute reduction in floor effects (percentage points) 0.14 0.25 1.43 4.29 1.64 0.21
Number of studies reporting on floor effects 18 18 18 18 18 5
Number of studies reporting lower floor effects for the 5L than for the 3L 7 6 13 16 14 3
MO SC UA PD AD ‘11111’
Ceiling
Range of ceiling effects for the 3L (%) 10.2–97.7 61.4–99.5 10.8–94.8 2.3–80.3 24.5–88.0 0.6–68.0
Range of ceiling effects for the 5L (%) 4.0–96.5 60.2–99.5 9.1–93.1 0.6–71.2 17.9–82.0 0–55.0
Range of absolute reduction in ceiling
effects (percentage points)
-0.25 to 16.9 -1.3 to 30.0 0.8–21.3 1.5–20.0 -3.4 to 19.7 -0.5 to 16.7
Mean absolute reduction in ceiling effects
(percentage points)
5.73 4.15 4.88 6.77 6.17 6.50
Number of studies reporting on ceiling effects 20 20 20 20 20 22
Number of studies reporting lower ceiling
effects for the 5L than for the 3L
19 16 20 20 18 19
Number of studies reporting\15% ceiling
for the 3L/5L
1/2 0/0 1/2 3/3 0/0 7/8
The absolute reduction in floor effects was calculated by subtracting the number or percentage of the reported highest level of problems/‘55555’
for the 5L by the number or percentage of the reported highest level of problems/‘33333’ for the 3L, respectively. The absolute reduction in
ceiling effects was calculated by subtracting the number or percentage of reported ‘no problems’/‘11111’ for the 5L by the number or percentage
of reported ‘no problems’/‘11111’ for the 3L, respectively
MO Mobility, SC Self-Care, UA Usual Activities, PD Pain/Discomfort, AD Anxiety/Depression
Measurement Properties of EQ-5D-3L vs EQ-5D-5L
allows us to determine whether it has improved upon those
properties. This review systematically summarizes the
evidence of studies comparing the methodological prop-
erties of the EQ-5D-3L and EQ-5D-5L, with a special
focus on redistribution of responses, including ceiling
effects, floor effects, inconsistent responses, reliability and
responsiveness. In the face of the reviewed results, both
instruments demonstrated appropriateness for use in a wide
range of study populations, addressing a variety of research
questions and using different study designs. They show (1)
the 5L responses logically distribute from the 3L, and (2)
the 5L has advantages in terms of ceiling, (re-)distribution/
distributional properties and how the descriptive system is
used, but there are (3) some areas, such as responsiveness,
in which the evidence is mixed and further research is
needed. Furthermore, other aspects beyond the reviewed
methodological parameters are important when choosing
between 3L and 5L.
The low percentage of inconsistencies found in head-to-
head studies demonstrates that the 3L redistributes logi-
cally to the 5L and that results of the 5L and 3L are
comparable. The 5L is successful in reducing ceiling
effects; a smaller proportion of respondents reported
‘11111’ on the 5L than on the 3L, especially in healthier
samples. Thus, the 5L is suggested if the main goal is to
discriminate among patients with milder health states.
Moreover, the 5L outperformed the 3L when considering
Shannon’s H0, with H0 being approximately 1.5-fold higher
for the 5L compared with the 3L, without a relevant
decrease of J0.
Missing values are negligible for both instruments
demonstrating acceptance by respondents. Floor effects are
also negligible for both instruments, meaning few respon-
dents reported having the third or fifth levels of function in
EQ-5D dimensions (e.g. ‘unable to wash or dress myself’).
Most value sets assign negative weights to poor EQ-5D
health states, meaning respondents valued many of these
health states as worse than death (death is anchored at
zero).
There is mixed evidence for better reliability on
dimensional level, while evidence on index values shows
better performance of 5L. Evidence on comparative
responsiveness of the 3L and 5L is mixed [37, 42, 45]. This
is surprising since adding levels to the 3L was intended to
improve the responsiveness of the 3L. While two studies
found the 5L to be slightly more responsive than the 3L
when using non-parametric test statistics, Golicki et al. [42]
found the crosswalk-derived 5L index to be less responsive
than the 3L index when using several distribution-based
approaches. There could be an explanation for why Golicki
et al. conflicted with the other two studies. Crosswalk-
derived utility scores tend to underdetect health gains
[60–62]. For a preference-based instrument, it may be more
appropriate to assess how changes in 5L versus 3L index
scores are reflected in incremental cost-effectiveness ratios
(ICERs) or quality-adjusted life-years (QALYs) [63].
Fig. 2 Ceiling for the profile
(‘11111’) compared with the 3L
and the 5L. f.-up follow-up
I. Buchholz et al.
Furthermore, differences with how participants value 3L
versus 5L health states must be more closely examined
[64, 65]. More research into sensitivity to change of the 5L
and 3L is needed.
4.1 Limitations
This review has several limitations. Although all but two
studies directly compared the 3L and the 5L, there are
several reasons that the results of this review are difficult to
generalize. The data have been derived from (1) different
studies, (2) sampled from different population or patient
samples, (3) use different language versions or values sets
of the EQ-5D, and (4) use varying research designs (e.g.
order of 3L vs. 5L, placing other, and how many, ques-
tionnaires in between 3L and 5L). Due to the differing
methods, designs, analyses and potential cross-cultural
differences in EQ-5D response patterns [66], it was
Fig. 3 Ceiling for the profile by sample type: forest plot with study
proportions, pooled proportions, and 95% CI of reporting ‘11111’ of
the EQ-5D-3L against the EQ-5D-5L. CI confidence interval,
P proportion, N sample size, THA total hip arthroplasty, UK United
Kingdom, US United States
Fig. 4 Shannon’s H0 and J0 for the 3L and the 5L
Measurement Properties of EQ-5D-3L vs EQ-5D-5L
difficult to summarize results. There are no guidelines for
preference-based measures or established guidelines and
standards (such as, for example, COSMIN). The EuroQol
Group could create a task force to develop reporting
standards in order to ensure future studies are well-defined
and use more homogenous methods.
However, choosing between using the 3L and 5L
requires consideration of aspects beyond methodological
characteristics (which were specifically addressed in the
scope of this review), such as setting and respondents,
purpose of use, and availability of instruments and value
sets. For all self-assessment instruments, and for prefer-
ence-based instruments in particular, the choice of instru-
ment should always take into account the perspective of
those who complete the instrument, i.e. patients or
respondents. There is evidence that patients prefer the 5L
to the 3L, although the reason is not clear [8, 45, 67]. Fewer
patients reported problems filling in the EQ-5D-5L ques-
tionnaire, and more patients deem the 5L to be easier to
answer than the 3L and can find statements to describe their
own health state on the 5L.
Another crucial aspect is the available language version,
and, related to that, the availability of a value set to cal-
culate the index score for the target population. Currently,
both the 3L and 5L are available in more than 120 lan-
guages (3L:[170; 5L:[130) and for various administra-
tion modes (www.euroqol.org). To calculate an index
score, the availability of a value set for the target popula-
tion is necessary. The number of value sets available for
the 3L (at least 27) is much larger than for the 5L (at least
8), with the crosswalk serving as the interim scoring
method, while population-specific 5L value sets are being
developed. There are also some cases where a 5L value set
is available but a 3L is not; for those situations, population-
specific 3L scores cannot be calculated.
5 Conclusions
This review supports the use of both the 3L and the 5L in a
broad range of patients, populations, and countries. The 5L
performs slightly better in terms of reducing ‘ceiling’
effects, and similarly in many other distributional proper-
ties. More research must be conducted to clarify both
instruments’ performance on sensitivity to change and
reliability, for which our review found mixed results from a
few studies. The EuroQol group considering guiding end
users with the decision to use the 5L or 3L as the choice of
Fig. 5 Percentage of inconsistencies by dimension and overall. THR total hip replacement
I. Buchholz et al.
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instrument would be based on aspects beyond measurement
properties. The evidence presented in this paper can benefit
the development of new EQ-5D versions, such as a 5L
version of the child-friendly EQ-5D-Y [68], or exploring
additional dimensions to the current five-dimension format
(‘bolt-ons’) [69, 70].
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